Last updated: October 28, 2026
Antivenin (Micrurus fulvius) is a legacy equine-derived antivenom for eastern coral snake envenomation in the United States. Its commercial profile is defined by very low patient volume, difficult manufacturing, limited replacement supply, and high clinical value per treatment. The product does not have a meaningful active patent or exclusivity position. Its principal economic barrier is manufacturing capability and regulatory validation, not intellectual property.
No audited product-level revenue is publicly reported. The available evidence supports a small, procurement-driven market rather than a conventional branded-pharmaceutical market with scalable sales growth.
What is Antivenin (Micrurus fulvius)?
Antivenin (Micrurus fulvius) is an equine antivenom containing antibodies generated against eastern coral snake venom. It is intended to neutralize venom from Micrurus fulvius, the eastern coral snake found primarily in the southeastern United States.
| Attribute |
Product profile |
| Active biological material |
Equine-derived antibodies |
| Target envenomation |
Eastern coral snake |
| FDA category |
Biological antivenom |
| Primary use |
Treatment of clinically significant coral snake envenomation |
| Principal legacy manufacturer |
Wyeth Laboratories, later part of Pfizer |
| Current commercial position |
Legacy or discontinued U.S. supply status |
| Orange Book status |
Not listed as a conventional small-molecule drug |
| Biosimilar pathway |
Not directly applicable |
| Commercial demand |
Low volume, geographically concentrated |
| Main competitive issue |
Availability of replacement supply |
The product is distinct from CroFab, which is used for North American pit-viper envenomation, and Anavip, which is another pit-viper antivenom. Neither product is a direct substitute for coral snake antivenom.
What is the FDA status of Antivenin (Micrurus fulvius)?
Public FDA product records identify the legacy U.S. product as discontinued or no longer routinely marketed. Discontinued status does not by itself establish a safety withdrawal. In this case, the commercial problem has been associated with limited demand, production economics, and the difficulty of maintaining a dedicated antivenom manufacturing process for a rare indication.
FDA regulation of antivenoms is administered through the biologics framework. A replacement product would generally require an appropriate biologics license or another FDA-authorized pathway. A foreign antivenom cannot be treated as interchangeable with the legacy U.S. product solely because it targets coral snake venom.
The FDA’s shortage and expanded-access mechanisms can be relevant when no approved domestic product is commercially available. Those mechanisms do not create a permanent commercial license, establish automatic substitution, or eliminate manufacturing validation requirements. [1,2]
What is the FDA exclusivity timeline?
The product’s regulatory exclusivity period expired decades ago. The relevant commercial question is not whether the originator retains exclusivity, but whether a competitor can reproduce the product, demonstrate adequate potency against the relevant venom, satisfy sterility and consistency requirements, and secure an FDA authorization.
| Exclusivity category |
Current relevance |
| New chemical entity exclusivity |
Not applicable |
| Orphan-drug exclusivity |
No current enforceable period identified |
| Pediatric exclusivity |
Not applicable |
| Biologic reference-product exclusivity |
Historical product predates the modern reference-product framework |
| Patent-based exclusivity |
No material active patent barrier identified |
| Regulatory exclusivity |
Expired or not commercially controlling |
When does Antivenin (Micrurus fulvius) lose patent protection?
The product’s principal patent protection expired long ago, if any relevant composition or use patents existed. The commercial product is associated with an older biologic platform rather than a recently patented antibody sequence, recombinant protein, or proprietary delivery system.
No active Orange Book-listed patent estate appears to protect Antivenin (Micrurus fulvius). The Orange Book is primarily designed for approved small-molecule drugs and does not provide the central patent framework for this legacy antivenom.
How strong is the patent estate?
The patent estate is weak from a modern pharmaceutical investment perspective.
| IP category |
Assessment |
| Composition-of-matter patents |
No current commercially meaningful protection identified |
| Antibody sequence patents |
Not applicable to the legacy polyclonal product |
| Formulation patents |
No material active estate identified |
| Method-of-use patents |
No material active estate identified |
| Manufacturing patents |
Process know-how may exist, but public evidence of enforceable blocking patents is limited |
| Trademark protection |
Brand protection would not prevent competing antivenom approval |
| Trade secrets |
Potentially important for immunization, purification, potency testing, and release controls |
The key barrier is know-how. A replacement manufacturer would need to control venom sourcing, horse immunization, antibody purification, formulation, stability, potency assays, and batch release. Those capabilities can create a practical barrier even where formal patent protection is weak.
What formulations are protected by Antivenin (Micrurus fulvius)?
The legacy product is a parenteral, equine-derived antivenom supplied for intravenous administration after reconstitution or dilution according to product instructions. It is not a sustained-release formulation, oral product, autoinjector, or recombinant antibody therapy.
No current formulation patent estate has been identified as protecting the marketed product. Any new formulation could still require clinical, analytical, and manufacturing validation. A competitor could not rely on a patent-free status to avoid demonstrating product quality and clinical suitability.
Potential future product formats include:
- Purified F(ab')2 or Fab antibody fragments
- Recombinant monoclonal or oligoclonal antibodies
- Lyophilized products with improved stability
- Region-specific antivenoms covering multiple coral snake species
- Multi-species antivenoms combining coral snake and pit-viper coverage
These would be new product-development programs rather than ordinary generic substitutions.
How large is the U.S. coral snake antivenom market?
The market is small and episodic. Coral snake bites are uncommon relative to pit-viper bites, and many suspected bites do not produce clinically significant envenomation. Demand is concentrated in southeastern states, poison-control networks, tertiary hospitals, and emergency departments.
Public surveillance generally reports only a small number of coral snake exposures each year compared with the total number of venomous snakebite cases. Case counts vary by reporting system, geography, and whether suspected rather than confirmed bites are included. [3,4]
The market has four characteristics:
- Low annual unit demand.
- High variability between years.
- Severe consequences from stockouts.
- High fixed manufacturing costs relative to annual volume.
This structure makes ordinary commercial pricing difficult. A manufacturer must maintain production, testing, and inventory despite a small number of treated patients. Hospitals may also hold product for years, which creates expiration and replacement costs.
What drives revenue?
Revenue is driven less by patient volume than by the number of stocked institutions, inventory replacement cycles, emergency procurement, and contract pricing.
| Revenue driver |
Effect on market |
| Confirmed envenomation cases |
Creates treatment demand |
| Hospital stocking policies |
Determines baseline inventory |
| Product shelf life |
Creates recurring replacement purchases |
| Emergency procurement |
Can increase per-treatment revenue |
| Government or regional stockpiles |
Stabilizes demand |
| Number of vials per treatment |
Increases revenue per patient |
| Manufacturing batch size |
Determines cost efficiency |
| Geographic distribution |
Raises logistics and inventory costs |
No reliable public source establishes annual U.S. revenue for Antivenin (Micrurus fulvius). The absence of product-level revenue reporting is consistent with a legacy product that was privately supplied and not separately reported by its corporate owner.
What is the financial trajectory for Antivenin (Micrurus fulvius)?
The product’s trajectory is best described as decline, supply contraction, and potential replacement-market reopening.
| Period |
Market condition |
Financial implication |
| Legacy Wyeth period |
Established domestic antivenom with limited demand |
Low-volume maintenance product |
| Pfizer ownership period |
Product inherited within a large pharmaceutical portfolio |
Limited strategic fit |
| Discontinuation or supply interruption |
Dedicated production became difficult to justify |
Revenue declined or ceased |
| Post-discontinuation period |
Hospitals and poison centers depended on residual or alternative supply |
Scarcity value increased |
| Replacement-market phase |
Potential entry by a specialist biologics or antivenom developer |
Revenue depends on contracts and stockpiling |
The asset is unlikely to generate conventional blockbuster economics. A replacement product could still achieve attractive margins if it secures:
- Long-term hospital purchasing agreements.
- Government preparedness contracts.
- Regional poison-center distribution.
- Minimum-volume procurement commitments.
- Reimbursement support for emergency departments.
- Inventory replacement programs.
- Priority access arrangements for rural hospitals.
The commercial case is therefore closer to a specialty biologic, public-health reserve product, or strategic preparedness asset than to a broad hospital pharmaceutical.
Are there generic or biosimilar competitors?
There is no ordinary generic competition in the conventional Hatch-Waxman sense. The product is a biologic antivenom with complex source material and potency characteristics. A competing manufacturer would likely need to develop a separately authorized biological product rather than file a simple abbreviated generic application.
A biosimilar pathway is also not a straightforward fit. The legacy product is polyclonal and equine-derived, with biological variability that differs from modern monoclonal antibody reference products. A new competitor could instead pursue:
- A standalone biologics license application.
- A regionally authorized foreign product followed by FDA review or importation.
- A reformulated equine antivenom.
- A purified antibody-fragment product.
- A recombinant antibody product.
The scientific and regulatory burden would be material. Comparative analytical work would need to address venom neutralization, potency, specificity, immunogenicity, purity, aggregation, sterility, stability, and lot-to-lot consistency.
What manufacturing and intellectual-property barriers exist?
Manufacturing is the central barrier to entry.
Venom sourcing and immunization
The manufacturer must obtain consistent eastern coral snake venom and maintain a controlled horse-immunization program or another validated antibody-generation platform. Venom composition can vary by geography, age, season, and extraction process.
Potency and release testing
The product requires validated assays that demonstrate neutralization of the relevant venom activity. This can be more difficult than standard identity and purity testing because clinical performance depends on functional venom neutralization.
Scale economics
A facility designed for antivenom production may have substantial fixed costs. Annual demand may be too low to support a dedicated plant unless the manufacturer produces several antivenoms or obtains public-sector commitments.
Supply-chain resilience
A viable producer must manage horse care, venom supply, sterile filling, cold-chain or controlled-storage logistics, and emergency distribution. These requirements raise working-capital costs and make inventory write-offs significant.
IP position
Publicly visible patent protection is not the principal barrier. Trade secrets and regulatory know-how may matter more than patents, particularly in immunization protocols, purification steps, and release assays.
Which companies are challenging the legacy product?
No major branded pharmaceutical company has publicly established a broad U.S. commercial replacement franchise for Antivenin (Micrurus fulvius comparable to CroFab’s position in pit-viper treatment.
The competitive landscape consists of:
- Legacy-product rights holders and their successors.
- Specialist antivenom manufacturers.
- Public-sector or academic development groups.
- Foreign manufacturers with coral-snake antivenom platforms.
- Biotech developers pursuing recombinant or fragment-based antibodies.
Foreign antivenoms may target related Micrurus species, but cross-species coverage cannot be assumed. Regulatory acceptance would depend on product-specific evidence rather than the general label "coral snake antivenom."
What is the Paragraph IV and litigation status?
No material current Paragraph IV litigation has been identified for Antivenin (Micrurus fulvius). That result is expected because the product is not supported by a conventional active Orange Book patent listing and lacks a large branded market that would attract routine generic challenges.
No significant public patent litigation or settlement agreement is identified as affecting current U.S. market access. Any future dispute is more likely to concern:
- Regulatory approval or importation.
- Product substitution.
- Distribution rights.
- Government procurement.
- Manufacturing know-how.
- Trademark use.
- Contractual supply obligations.
A Paragraph IV launch strategy would not be the normal route for a new coral snake antivenom. A developer would more likely pursue an independent biologics authorization and compete on availability, clinical evidence, quality, and contracting.
What licensing deals affect the market?
No major current licensing transaction has been publicly disclosed that establishes a dominant U.S. commercial successor to the legacy product.
A viable licensing transaction would likely involve one of three structures:
| Licensing structure |
Strategic purpose |
| Foreign manufacturer to U.S. specialty distributor |
Accelerates market access |
| Biotech developer to established biologics manufacturer |
Provides production and regulatory capacity |
| Government or hospital consortium agreement |
Creates minimum-volume demand |
| Academic or public-sector collaboration |
Supports venom characterization and clinical evidence |
The most important deal term would be guaranteed demand rather than headline royalty rate. Without minimum purchases or stockpile commitments, a licensee may not be able to support the manufacturing platform.
What generic launch scenarios exist?
Scenario 1: No replacement product
Hospitals continue to manage risk through limited inventories, poison-center coordination, and case-by-case sourcing. The market remains supply constrained, with no stable commercial growth.
Scenario 2: Imported antivenom
An overseas product enters through an FDA-authorized mechanism. This could improve access but would face species-coverage, labeling, manufacturing, and procurement hurdles.
Scenario 3: New equine antivenom
A specialist manufacturer recreates or modernizes the legacy platform. This is the most direct replacement but requires substantial production and validation investment.
Scenario 4: Recombinant antibody product
A developer creates a more consistent antibody therapy. The product could improve stability and reduce dependence on horses, but development costs and clinical validation would be higher.
Scenario 5: Multi-antivenom platform
A manufacturer combines coral snake coverage with other regional venoms. This could improve plant utilization and support a broader commercial case, but it could complicate dosing, regulatory evidence, and reimbursement.
How does Antivenin (Micrurus fulvius) compare with CroFab and Anavip?
| Product |
Target |
Commercial market |
Competitive position |
| Antivenin (Micrurus fulvius) |
Eastern coral snake |
Very small and regional |
Legacy or limited-supply product |
| CroFab |
North American pit vipers |
Larger U.S. hospital market |
Established branded antivenom |
| Anavip |
North American pit vipers |
Established but narrower than CroFab |
Direct pit-viper competitor to CroFab |
| Foreign coral-snake antivenoms |
Species-dependent |
Potential replacement market |
Coverage and regulatory comparability vary |
CroFab and Anavip benefit from materially larger pit-viper treatment demand. That supports dedicated commercial infrastructure, sales teams, hospital contracts, and inventory management. Antivenin (Micrurus fulvius) lacks the same volume economics.
What is the investment outlook?
The investment case is defensive and infrastructure-oriented rather than growth-oriented.
Potential strengths include:
- Limited direct competition.
- High clinical necessity during qualifying emergencies.
- Ability to obtain premium pricing for reliable supply.
- Potential government support.
- Low substitution risk once a product is stocked and approved.
Principal weaknesses include:
- Small addressable patient population.
- High fixed manufacturing costs.
- Difficult demand forecasting.
- Expiration and inventory losses.
- Limited patent protection.
- Complex regulatory comparability.
- Dependence on institutional procurement.
The strongest commercial model would combine coral snake antivenom with additional antivenom products, contract manufacturing, or a public-health preparedness portfolio. A standalone product would face substantial margin pressure unless supported by guaranteed purchases or strategic stockpiling.
Key Takeaways
- Antivenin (Micrurus fulvius) addresses a rare but medically serious U.S. indication.
- The legacy product has no material current patent or Orange Book advantage.
- Regulatory exclusivity expired or is not commercially controlling.
- Generic and biosimilar competition is not the correct framework; a replacement product would likely require an independent biologics authorization.
- No audited public revenue series exists for the product.
- The market is small, regional, and driven by hospital inventory rather than prescription volume.
- Manufacturing know-how, venom sourcing, potency testing, and regulatory validation are the principal barriers.
- A new entrant would need stockpile contracts, hospital commitments, or a broader antivenom portfolio to achieve attractive economics.
- No material current Paragraph IV litigation, patent settlement, or dominant licensing transaction has been identified.
- The most credible commercial opportunity is a reliable replacement or multi-antivenom platform, not a conventional branded-drug launch.
Frequently Asked Questions
Is Antivenin (Micrurus fulvius) still commercially available in the United States?
Public FDA records identify the legacy product as discontinued or no longer routinely marketed. Availability may depend on residual inventory, specialized distribution, regulatory mechanisms, or alternative products.
Does CroFab treat eastern coral snake bites?
CroFab is indicated for North American pit-viper envenomation and is not a direct substitute for eastern coral snake antivenom.
Is coral snake antivenom an orphan drug?
The indication is rare and could support orphan-drug considerations for a new product, but no current enforceable orphan exclusivity period for the legacy product has been identified.
Can a foreign coral snake antivenom be automatically used in the United States?
No. Species coverage, manufacturing quality, FDA authorization, labeling, potency, and importation status must be evaluated for the specific product.
Could recombinant antibodies replace equine coral snake antivenom?
Yes, in principle. Recombinant antibodies could reduce animal dependence and improve consistency, but development would require substantial venom-neutralization, safety, manufacturing, and regulatory evidence.
References
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA and biologics product information: Antivenin (Micrurus fulvius) [Equine]. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Biologics license applications and product classification. https://www.fda.gov/vaccines-blood-biologics
-
Centers for Disease Control and Prevention. (n.d.). Venomous snakes and snakebite prevention. https://www.cdc.gov/
-
American Association of Poison Control Centers. (n.d.). Annual report of the National Poison Data System. https://aapcc.org/annual-reports/
